Intuitive Surgical, Inc. (ISRG) stock analysis

Healthcare · Medical Instruments & Supplies

From the 10-K filed 2026-02-03

Business type: Franchise

How it makes money

Intuitive earns revenue by selling robotic surgical systems, recurring instruments and accessories, and ongoing support services to healthcare providers.

Hospitals and healthcare systems purchase complex robotic platforms, such as da Vinci surgical systems and Ion endoluminal systems, along with learning services and technical support. The variable that most moves profit is the recurring purchase of instruments and accessories used in every single procedure performed on these systems. As the total volume of surgical procedures grows, hospitals continuously reorder specialized instruments, directly driving ongoing revenue and profit growth for the company.

What protects it: the moat

Intuitive protects its market position through a large installed base of robotic systems, proprietary technology, and established clinical relationships.

The company relies on its massive installed base of multi-generation surgical systems globally, extensive regulatory clearances across multiple medical specialties, and continuous technological refinements built over decades. Management claims that its comprehensive ecosystem, digital portfolio, and peer-reviewed clinical evidence deliver differentiated economic and clinical value that discourages hospitals from switching to competing platforms.

What growth costs

Intuitive does not disclose specific figures for its ongoing reinvestment costs in this filing.

The provided text discusses the commercial rollout of new systems like the da Vinci 5 and ongoing international expansion efforts, but it does not provide specific financial figures or expenditure amounts dedicated to research and development, manufacturing plants, working capital, or marketing.

What could damage it

Alternative medical treatments or weight loss drugs could reduce surgical procedure volumes, thereby decreasing recurring instrument sales and permanently impairing earnings.

If newly approved pharmaceutical treatments or emerging diagnostic techniques become widely accepted as more effective or less expensive than surgery, patients may forgo surgical procedures altogether. A sustained reduction in surgical procedures performed on da Vinci systems directly decreases the demand for recurring instruments and accessories, eroding the high-margin revenue stream that supports the business.

About Intuitive Surgical, Inc.

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.

More on ISRG

Other companies in Medical Instruments & Supplies